Literature DB >> 28615420

Insulin resistance among obese middle-aged is associated with decreased cerebrovascular reactivity.

Olivia H Frosch1, Po Lai Yau1, Ricardo S Osorio1, Henry Rusinek1, Pippa Storey1, Antonio Convit2.   

Abstract

OBJECTIVE: To evaluate differences in cerebrovascular reactivity (CVR) to mild hypercapnia in obese/overweight individuals with and without insulin resistance (IR) compared to comparable lean controls.
METHODS: A total of 60 cognitively normal participants (20 lean controls and 24 obese/overweight individuals with and 16 without IR) were evaluated using a high spatial resolution arterial spin labeling MRI technique at rest and during mild hypercapnia. We analyzed group differences in CVR in cerebral cortex and ascertained the relationships between CVR, IR, and body mass index (BMI).
RESULTS: Obese/overweight participants with and without IR had significantly lower CVR to hypercapnia than lean controls after controlling for age, sex, and the presence of hypertension (F2,53 = 5.578, p = 0.006 [Formula: see text] = 0.174). In the obese/overweight participants with IR, there was a significant correlation between higher CVR and a measure of insulin sensitivity, even after accounting for BMI (rp = 0.575, p = 0.004). In contrast, there was no relationship between CVR and BMI when controlling for IR. No such relationships existed for the other 2 groups.
CONCLUSIONS: IR is associated with impaired CVR; the relationship appears to be driven by the degree of IR and not by obesity. These rarely reported results suggest that early forms of cerebrovascular dysfunction exist among obese middle-aged individuals with significant IR but without type 2 diabetes mellitus. These functional vascular abnormalities may help explain the associations among IR, diabetes, and dementia, and suggest that interventions aiming to improve IR or CVR may help prevent cognitive decline later in life.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Year:  2017        PMID: 28615420      PMCID: PMC5513815          DOI: 10.1212/WNL.0000000000004110

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

1.  Cognitive impairment in nondiabetic middle-aged and older adults is associated with insulin resistance.

Authors:  H Bruehl; V Sweat; J Hassenstab; V Polyakov; A Convit
Journal:  J Clin Exp Neuropsychol       Date:  2010-06       Impact factor: 2.475

Review 2.  Human cerebral neuropathology of Type 2 diabetes mellitus.

Authors:  Peter T Nelson; Charles D Smith; Erin A Abner; Frederick A Schmitt; Stephen W Scheff; Gregory J Davis; Jeffrey N Keller; Gregory A Jicha; Daron Davis; Wang Wang-Xia; Adria Hartman; Douglas G Katz; William R Markesbery
Journal:  Biochim Biophys Acta       Date:  2008-08-22

Review 3.  Endotheliopathy precedes type 2 diabetes.

Authors:  J E Tooke; K L Goh
Journal:  Diabetes Care       Date:  1998-12       Impact factor: 19.112

4.  Obesity: cerebral damage in obesity-associated metabolic syndrome.

Authors:  Henry Rusinek; Antonio Convit
Journal:  Nat Rev Endocrinol       Date:  2014-08-12       Impact factor: 43.330

5.  Hippocampal blood flow in normal aging measured with arterial spin labeling at 3T.

Authors:  Henry Rusinek; Miroslaw Brys; Lidia Glodzik; Remigiusz Switalski; Wai-Hon Tsui; Francois Haas; Kellyanne McGorty; Qun Chen; Mony J de Leon
Journal:  Magn Reson Med       Date:  2011-01       Impact factor: 4.668

6.  Preliminary evidence for brain complications in obese adolescents with type 2 diabetes mellitus.

Authors:  P L Yau; D C Javier; C M Ryan; W H Tsui; B A Ardekani; S Ten; A Convit
Journal:  Diabetologia       Date:  2010-07-30       Impact factor: 10.122

Review 7.  Endothelial dysfunction, inflammation, and apoptosis in diabetes mellitus.

Authors:  Inge A M van den Oever; Hennie G Raterman; Mike T Nurmohamed; Suat Simsek
Journal:  Mediators Inflamm       Date:  2010-06-15       Impact factor: 4.711

8.  Acute hyperglycemia reduces cerebrovascular reactivity: the role of glycemic variability.

Authors:  Ilaria Giordani; Alessandra Di Flaviani; Fabiana Picconi; Ilaria Malandrucco; Dorina Ylli; Paola Palazzo; Riccardo Altavilla; Fabrizio Vernieri; Francesco Passarelli; Silvia Donno; Davide Lauro; Patrizio Pasqualetti; Simona Frontoni
Journal:  J Clin Endocrinol Metab       Date:  2014-05-30       Impact factor: 5.958

Review 9.  Dementia and cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions.

Authors:  Geert Jan Biessels; Mark W J Strachan; Frank L J Visseren; L Jaap Kappelle; Rachel A Whitmer
Journal:  Lancet Diabetes Endocrinol       Date:  2013-10-18       Impact factor: 32.069

10.  Elevated BMI is associated with decreased blood flow in the prefrontal cortex using SPECT imaging in healthy adults.

Authors:  Kristen C Willeumier; Derek V Taylor; Daniel G Amen
Journal:  Obesity (Silver Spring)       Date:  2011-02-10       Impact factor: 5.002

View more
  13 in total

1.  Sex-related differences in the prevalence of cognitive impairment among overweight and obese adults with type 2 diabetes.

Authors:  Mark A Espeland; Owen Carmichael; Sevil Yasar; Christina Hugenschmidt; William Hazzard; Kathleen M Hayden; Stephen R Rapp; Rebecca Neiberg; Karen C Johnson; Siobhan Hoscheidt; Michelle M Mielke
Journal:  Alzheimers Dement       Date:  2018-07-05       Impact factor: 21.566

2.  Telmisartan use and risk of dementia in type 2 diabetes patients with hypertension: A population-based cohort study.

Authors:  Chi-Hung Liu; Pi-Shan Sung; Yan-Rong Li; Wen-Kuan Huang; Tay-Wey Lee; Chin-Chang Huang; Tsong-Hai Lee; Tien-Hsing Chen; Yi-Chia Wei
Journal:  PLoS Med       Date:  2021-07-19       Impact factor: 11.069

3.  Lifestyle and vascular risk effects on MRI-based biomarkers of Alzheimer's disease: a cross-sectional study of middle-aged adults from the broader New York City area.

Authors:  Lisa Mosconi; Michelle Walters; Joanna Sterling; Crystal Quinn; Pauline McHugh; Randolph E Andrews; Dawn C Matthews; Christine Ganzer; Ricardo S Osorio; Richard S Isaacson; Mony J De Leon; Antonio Convit
Journal:  BMJ Open       Date:  2018-03-23       Impact factor: 2.692

4.  Oridonin prevents insulin resistance-mediated cognitive disorder through PTEN/Akt pathway and autophagy in minimal hepatic encephalopathy.

Authors:  Fangfang Wen; Weishan Zhuge; Jian Wang; Xiaoai Lu; Ruimin You; Leping Liu; Qichuan Zhuge; Saidan Ding
Journal:  J Cell Mol Med       Date:  2019-09-30       Impact factor: 5.310

Review 5.  Intranasal Insulin for Alzheimer's Disease.

Authors:  Manfred Hallschmid
Journal:  CNS Drugs       Date:  2021-01-30       Impact factor: 5.749

6.  Cerebrovascular Reactivity Measurement Using Magnetic Resonance Imaging: A Systematic Review.

Authors:  Emilie Sleight; Michael S Stringer; Ian Marshall; Joanna M Wardlaw; Michael J Thrippleton
Journal:  Front Physiol       Date:  2021-02-25       Impact factor: 4.566

Review 7.  Insulin Resistance as a Therapeutic Target in the Treatment of Alzheimer's Disease: A State-of-the-Art Review.

Authors:  Christian Benedict; Claudia A Grillo
Journal:  Front Neurosci       Date:  2018-04-10       Impact factor: 4.677

8.  Is insulin resistance the cause of fibromyalgia? A preliminary report.

Authors:  Miguel A Pappolla; Laxmaiah Manchikanti; Clark R Andersen; Nigel H Greig; Fawad Ahmed; Xiang Fang; Michael A Seffinger; Andrea M Trescot
Journal:  PLoS One       Date:  2019-05-06       Impact factor: 3.240

9.  Impact of bariatric surgery on cerebral vascular reactivity and cognitive function: a non-randomized pilot study.

Authors:  Wesley J Tucker; Binu P Thomas; R Matthew Brothers; Michael D Nelson; Nancy Puzziferri; T Jake Samuel; Vlad G Zaha; Ildiko Lingvay; Jaime Almandoz; Jing Wang; Edward A Gonzales
Journal:  Pilot Feasibility Stud       Date:  2020-02-13

10.  TREM-2-p38 MAPK signaling regulates neuroinflammation during chronic cerebral hypoperfusion combined with diabetes mellitus.

Authors:  Jiawei Zhang; Yu Liu; Yaling Zheng; Yan Luo; Yu Du; Yao Zhao; Jian Guan; Xiaojie Zhang; Jianliang Fu
Journal:  J Neuroinflammation       Date:  2020-01-03       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.